AbbVie (ABBV) Cost of Revenue (2012 - 2026)

AbbVie (ABBV) has reported Cost of Revenue for 15 consecutive years, with $4.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 5.4% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $18.4 billion (up 9.56% YoY), while the FY2025 annual figure was $18.2 billion, up 7.69% from the prior year.
• Cost of Revenue eased to $4.2 billion in Q1 2026 per ABBV's latest filing, from $4.6 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $6.5 billion in Q3 2023 and bottomed at $4.0 billion in Q1 2023.
• Historically, Cost of Revenue has averaged $4.5 billion across 5 years, with a median of $4.2 billion in 2026.
• Annual changes were most pronounced in 2023 — Cost of Revenue surged 36.79% — and 2024, when it sank 35.05%.
• AbbVie's Cost of Revenue stood at $4.2 billion in 2022, then soared by 36.79% to $5.7 billion in 2023, then retreated by 22.93% to $4.4 billion in 2024, then increased by 3.55% to $4.6 billion in 2025, then retreated by 7.34% to $4.2 billion in 2026.
• Business Quant data shows ABBV's Cost of Revenue at $4.2 billion in Q1 2026, $4.6 billion in Q4 2025, and $5.3 billion in Q3 2025.